Please enable JavaScript.
Coggle requires JavaScript to display documents.
The Future Role of Cardio-oncologists (Cardio-oncology subspeciality…
The Future Role of Cardio-oncologists
Cardio-oncology
subspeciality
Treatment requires tight co-operation
between oncologist and cardiologist
Prevent cardiotoxicity, detect early signs of cardiotoxicity
Take appropriate measures to solve complications
Diagnosis cardiovascular complications
of cancer treatment
Was based on a decrease of left ventricular ejection fraction of at least 10 % to a level below normal
Methods such as
cardiac MRI
multigated radionuclide angiography
2D and 3D echocardiography
Factors for CV risk
current myocardial disease
previous cardiotoxic
cancer treatment
demographic risk factors
life-style risk factors
Regimen of the diagnostic tools for the detection of cardiotoxicity
Nuclear cardiac imaging
Cardiac MRI
Echocardiography
Biomarker assessment
ECG
Cardiovascular disease and cancer
Cardiotoxicity
Most common cause of morbidity
and mortality in cancer survivors
Depression of the left ventricle function
Heart failure in patients treated with anthracyclines
Myocardial dysfunction
Associated with
anticancer treatment (anthracyclines, alkylating
agents, tyrosine kinase inhibitors, ETC)
Management of patients treated with potentially cardiotoxic drugs
Asymptomatic patients with significantly decreased ejection fraction,
Treatment with angiotensin-converting enzyme inhibitors in combination with beta blockers
Prevention of further decrease
of LVEF